Segetis

About Segetis

Segetis, Inc. operated as a green chemistry company, focusing on the development and commercialization of renewable polymers from its headquarters in Golden Valley, Minnesota. Founded in 2006, the company established a business-to-business model centered on its proprietary Javelin™ Technology. This thermochemical process converted non-food biomass, such as wood pulp and corn stover, into levulinic acid and its derivatives, particularly levulinic ketals. These bio-based molecules served as substitutes for petroleum-derived chemicals in a variety of industrial and consumer products.

The company's product portfolio targeted several large markets, offering bio-based plasticizers, solvents, and emulsifiers. These materials were designed for application in home cleaning products, adhesives, bioplastics, and personal care items like fragrances. Segetis aimed to provide chemicals that were not only derived from renewable resources but could also compete on cost and performance, stating its products could be cost-competitive with oil priced at $50 a barrel. A notable partnership was formed in 2011 with Method Products, a manufacturer of home cleaning supplies, which utilized Segetis' materials to replace fossil fuel-derived solvents in its product lines.

Financially, Segetis attracted significant venture capital, raising approximately $60 million over several funding rounds from investors including Khosla Ventures, DSM Venturing, and the Malaysian Life Sciences Capital Fund. The company operated a demonstration-scale plant in Minnesota capable of producing 250,000 pounds of levulinic ketals annually and was expanding capacity through toll manufacturing partnerships. The management team included CEO Atul Thakrar, a veteran of the chemical industry. In February 2016, Segetis was acquired by GFBiochemicals, an Italian producer of levulinic acid. The acquisition included Segetis' production plant, assets, and its extensive intellectual property portfolio, which consisted of over 250 patent applications worldwide. This transaction provided GFBiochemicals with a direct entry into the U.S. market and access to Segetis' derivatives technology, accelerating its strategy to expand the applications for levulinic acid.